Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | LIPE | Q05469 | 4/20 | 0.37 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.37 |
| ▸ | MAOB | P27338 | 2/20 | 0.33 |
| ▸ | MMP2 | P08253 | 2/20 | 0.33 |
| ▸ | MMP9 | P14780 | 2/20 | 0.33 |
| ▸ | MAOA | P21397 | 1/20 | 0.32 |
| ▸ | PPARG | P37231 | 2/20 | 0.32 |
| ▸ | PPARA | Q07869 | 2/20 | 0.32 |
| ▸ | BACE1 | P56817 | 1/20 | 0.32 |
| ▸ | LTA4H | P09960 | 1/20 | 0.32 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.32 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.32 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.32 |
| ▸ | ATM | Q13315 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7466202 | 0.88 | MEN1 (0.37) | MEN1KMT2ALIPEMAPK14MAOB | |
| SCHEMBL6695269 | 0.83 | MEN1 (0.38) | MEN1KMT2ALIPEMAPK14MAOB | |
| SCHEMBL6695270 | 0.83 | MEN1 (0.38) | MEN1KMT2ALIPEMAPK14MAOB | |
| SCHEMBL7545346 | 0.81 | MAPK14 (0.37) | MEN1KMT2ALIPEMAPK14MAOB | |
| SCHEMBL7467425 | 0.81 | MAOB (0.42) | MAOBMAOAPPARG | |
| SCHEMBL7492706 | 0.80 | HIF1A (0.42) | MEN1KMT2AMAPK14MAOBMAOA | |
| SCHEMBL6697613 | 0.80 | MEN1 (0.38) | MEN1KMT2ALIPEMAPK14MMP2 | |
| SCHEMBL7470567 | 0.79 | HIF1A (0.38) | MEN1KMT2AMAPK14MAOBS1PR1 | |
| SCHEMBL7470560 | 0.79 | HIF1A (0.38) | MEN1KMT2AMAPK14MAOBS1PR1 | |
| SCHEMBL6695416 | 0.78 | PTGS2 (0.34) | PPARGPPARAS1PR1PTGS2ATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040023806-A1 | N-phenylcarbamates having a microbicide insecticide and acaricide effect | BAYER AKTIENGESELLSCHAFT (DE) | 2004-02-05 | — | — | US | claimed |
| US-20040023806-A1 | N-phenylcarbamates having a microbicide insecticide and acaricide effect | BAYER AKTIENGESELLSCHAFT (DE) | 2004-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040023806-A1 | N-phenylcarbamates having a microbicide insecticide and acaricide effect | CBR3, CBR1, CYP1B1 | MEN1 3045/4885KMT2A 3292/4885LIPE 741/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.